120 related articles for article (PubMed ID: 36729405)
21. Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells.
Kim HS; Lee WJ; Lee SW; Chae HW; Kim DH; Oh Y
Horm Metab Res; 2010 Mar; 42(3):165-72. PubMed ID: 19960406
[TBL] [Abstract][Full Text] [Related]
22. SSi6 promotes cell death by apoptosis through cell cycle arrest and inhibits migration and invasion of MDA-MB-231 human breast cancer cells.
Luna-Dulcey L; da Silva JA; Cominetti MR
Anticancer Drugs; 2020 Jan; 31(1):35-43. PubMed ID: 31490285
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
24. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
Bonelli M; La Monica S; Fumarola C; Alfieri R
Biochem Pharmacol; 2019 Dec; 170():113676. PubMed ID: 31647925
[TBL] [Abstract][Full Text] [Related]
25. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
Wang H; Nicolay BN; Chick JM; Gao X; Geng Y; Ren H; Gao H; Yang G; Williams JA; Suski JM; Keibler MA; Sicinska E; Gerdemann U; Haining WN; Roberts TM; Polyak K; Gygi SP; Dyson NJ; Sicinski P
Nature; 2017 Jun; 546(7658):426-430. PubMed ID: 28607489
[TBL] [Abstract][Full Text] [Related]
26. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
27. Induced expression of miR-1250-5p exerts tumor suppressive role in triple-negative breast cancer cells.
Shuaib M; Kumar S
J Cell Biochem; 2023 Feb; 124(2):282-293. PubMed ID: 36548440
[TBL] [Abstract][Full Text] [Related]
28. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
29. CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms.
Skowron MA; Vermeulen M; Winkelhausen A; Becker TK; Bremmer F; Petzsch P; Schönberger S; Calaminus G; Köhrer K; Albers P; Nettersheim D
Br J Cancer; 2020 Aug; 123(3):378-391. PubMed ID: 32418994
[TBL] [Abstract][Full Text] [Related]
30. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
31. Centaurea cyanus extracted 13-O-acetylsolstitialin A decrease Bax/Bcl-2 ratio and expression of cyclin D1/Cdk-4 to induce apoptosis and cell cycle arrest in MCF-7 and MDA-MB-231 breast cancer cell lines.
Keyvanloo Shahrestanaki M; Bagheri M; Ghanadian M; Aghaei M; Jafari SM
J Cell Biochem; 2019 Oct; 120(10):18309-18319. PubMed ID: 31161672
[TBL] [Abstract][Full Text] [Related]
32. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
Said TK; Medina D
Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
[TBL] [Abstract][Full Text] [Related]
33. Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells.
Choupani E; Madjd Z; Saraygord-Afshari N; Kiani J; Hosseini A
PLoS One; 2022; 17(12):e0279522. PubMed ID: 36548336
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.
Thomas AL; Lind H; Hong A; Dokic D; Oppat K; Rosenthal E; Guo A; Thomas A; Hamden R; Jeruss JS
Cell Cycle; 2017 Aug; 16(15):1453-1464. PubMed ID: 28678584
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
van Caloen G; Schmitz S; El Baroudi M; Caignet X; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
Mol Cancer Ther; 2020 Mar; 19(3):777-789. PubMed ID: 31924739
[TBL] [Abstract][Full Text] [Related]
36. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
37. Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of cyclin-dependent kinase inhibitor 1A, cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple negative xenograft growth.
Chai Y; Lee HJ; Shaik AA; Nkhata K; Xing C; Zhang J; Jeong SJ; Kim SH; Lu J
Breast Cancer Res; 2010; 12(5):R67. PubMed ID: 20809980
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor potential of 15,16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis.
Tsai SL; Suk FM; Wang CI; Liu DZ; Hou WC; Lin PJ; Hung LF; Liang YC
Biochem Pharmacol; 2007 Dec; 74(11):1575-86. PubMed ID: 17869226
[TBL] [Abstract][Full Text] [Related]
39. Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER
Marinelli O; Romagnoli E; Maggi F; Nabissi M; Amantini C; Morelli MB; Santoni M; Battelli N; Santoni G
BMC Cancer; 2020 Nov; 20(1):1119. PubMed ID: 33213401
[TBL] [Abstract][Full Text] [Related]
40. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]